The use of biomarkers to identify patients who can benefit from treatment with a specific
anticancer agent has the potential to both improve patient care and accelerate drug …

Tyrosine kinase inhibitors (TKIs) are currently used by most oncologists. Among their side
effects, thyroid dysfunctions are nowadays clearly observed. Whereas changes in thyroid …

Summary Background The phase 3 LUME-Lung 1 study assessed the efficacy and safety of
docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC) …

Introduction This randomised double-blind placebo-controlled study evaluated the addition
of cediranib, an inhibitor of vascular endothelial growth factor receptors 1–3, to standard …

Tumor tissue biomarkers are the basis for targeted therapy in non-small cell lung cancer
(NSCLC). These biomarkers either reflect the target of the specific drug or some factor that …

The design, synthesis and biological evaluations of fourteen 4-substituted 2, 6-dimethylfuro
[2, 3-d] pyrimidines are reported. Four compounds (11–13, 15) inhibit vascular endothelial …

There is a major unmet medical need for effective and well-tolerated treatment options for
patients with advanced nonsmall cell lung cancer (NSCLC), in both first-line and …

Background There is growing interest in defining the somatic mutations associated with
small-cell lung cancer (SCLC). Unfortunately, a serious blockade to genomic analyses of …

We performed a systematic review and meta-analysis of thyroid function abnormalities
associated with seven vascular endothelial growth factor receptor (VEGFR) targeted tyrosine …

The need to find new EGFR inhibitors for use in combination with radiotherapy in the
treatment of solid tumors has drawn our attention to compounds derived from genistein, a …